Using Siltuximab to treat antibody-mediated rejection after lung transplants
Official title: A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation
Funded at University of Utah · NIH-10925203 · Data updated 2026-11-12
This study is looking at how well Siltuximab, a medication that helps with immune responses, can help patients who are having problems after a lung transplant due to antibody-mediated rejection, with the goal of improving their health and recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $283,671 |
| NIH project number | 7R61HL169189-02 |
| Project ID | NIH-10925203 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have undergone lung transplantation and are experiencing symptoms of antibody-mediated rejection.
✕Less likely to help
Patients who have not received a lung transplant or those without evidence of antibody-mediated rejection may not benefit from this research.
What this research studies
This research investigates the use of Siltuximab, a medication that targets specific immune responses, to treat patients experiencing antibody-mediated rejection (AMR) after lung transplantation. AMR is a serious condition that can lead to chronic lung allograft dysfunction and significantly impacts survival rates. The study aims to assess the safety and effectiveness of Siltuximab in improving outcomes for these patients. Participants will be closely monitored to evaluate their response to the treatment and any potential side effects.
Why it matters
Potential benefit: If successful, this research could improve survival rates and quality of life for lung transplant recipients facing antibody-mediated rejection.
How similar studies have gone: While there have been various treatments for AMR, this approach using Siltuximab is novel and has not been extensively tested in randomized controlled trials.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Hachem, Ramsey — University of Utah
- Study coordinator: Hachem, Ramsey
Related research
Other NIH-funded projects on the same topics.
-
Phase 1 trial of siltuximab for antibody-mediated rejection after lung transplant
A early-stage study tests whether siltuximab can help people who have antibody-mediated rejection after lung transplantation.
-
Targeted delivery of immune-suppressing agents to the lung graft to prevent rejection
A study at Northwestern University will test a new, targeted approach to prevent lung transplant rejection by delivering immune-suppressing drugs directly to the graft while blocking early signals that trigger rejection.
-
Siltuximab for antibody-mediated rejection after lung transplant
This trial gives siltuximab to people with antibody-mediated rejection after a lung transplant to try to control the immune response harming the new lung.
-
Role of plasma cells in chronic rejection after lung transplantation
This research looks at how certain immune cells called plasma cells may drive chronic rejection in people who have had lung transplants and how this could lead to new ways to protect the transplant.
-
Non-invasive infection detection after lung transplant
A non-invasive blood test using phage-based signals could help doctors detect lung infections early in people who have had a lung transplant.
-
Investigating the role of plasma cells in lung transplant rejection
This study is looking at how certain immune cells, called plasma cells, might play a role in lung transplant rejection, especially for patients dealing with bronchiolitis obliterans syndrome, and it hopes to find new ways to help improve the success of lung transplants.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.